Effect of Riocigat on Patients with Chronic Thromboembolic Pulmonary Hypertension after Balloon Pulmonary Angioplasty

Effect of Riocigat on Patients with Chronic Thromboembolic Pulmonary Hypertension after Balloon Pulmonary Angioplasty - Effect of Riocigat on Patients with CTEPH after BPA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019599

Enrollment

Registered

2015-11-02

Start date

2015-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic thromboembolic pulmonary hypertension

Interventions

Riocigat, 1.5mg to 7.5mg, for 6 months control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as CTEPH Patietns with symptom of NYHA 1 or 2 Patients showing 20 to 30 mmHg of mean pulmonary arterial pressure or 200 to 400 dyne of pulmonary vascular resistance afetr BPA

Exclusion criteria

Exclusion criteria: Patients with unstable hemodynamics

Design outcomes

Primary

Measure	Time frame
Six minutes walk distance 6 months later	—

Countries

Japan

Contacts

Public ContactTatsuo Aoki

Tohoku University Graduate School of Medicine Cardiovascular Medicine

t.aoki@cardio.med.tohoku.ac.jp022-717-7153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026